Merck's (MRK) Grazoprevir/Elbasvir HCV Regimen Receives Two FDA Breakthrough Therapy Designations

April 8, 2015 7:37 AM EDT Send to a Friend
Merck (NYSE: MRK) announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login